Cargando…
Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria
BACKGROUND: The RECIST guidelines are commonly used in phase II and III clinical trials. The correct definition of response can be controversial in some situations, as in the case we describe. CASE PRESENTATION: A 43 year-old man with advanced gastric cancer was enrolled in a phase II trial where he...
Autores principales: | Amoroso, Vito, Pittiani, Frida, Grisanti, Salvatore, Valcamonico, Francesca, Simoncini, Edda, Ferrari, Vittorio D, Marini, Giovanni |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1896169/ https://www.ncbi.nlm.nih.gov/pubmed/17540044 http://dx.doi.org/10.1186/1471-2407-7-94 |
Ejemplares similares
-
RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015) -
Circulating Tumor Cells and Cardiac Metastasis from Esophageal Cancer: A Case Report
por: Consoli, Francesca, et al.
Publicado: (2011) -
Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021) -
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020) -
Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)